Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues.
Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues.
复制标题
DOI：
10.1093/schbul/23.2.247
复制
发表时间：
1997
影响因子：
6.6
通讯作者：
D. Ziedonis;T. George
中科院分区：
文献类型：
--
作者：
D. Ziedonis;T. George
尼古丁使用是一个主要的公共卫生问题，增加医疗发病率和死亡率。尼古丁的作用和精神分裂症的病理生物学有共同的神经生物学基础。吸烟改变药物的血液水平和有效性，改变精神症状，是其他物质滥用的线索。本文介绍了一个戒烟计划的评估24吸烟者精神分裂症。50%的人完成了该计划，40%的人减少了50%的使用，13%的人保持禁欲（一氧化碳验证）6个月。尼古丁替代、动机增强疗法和预防复发行为疗法是治疗的重要组成部分。在该人群的未来研究中，应评估高剂量尼古丁贴片、尼古丁咀嚼胶和贴片联合使用以及尼古丁替代增强药物的药物治疗策略。
Nicotine use is a major public health problem that increases medical morbidity and mortality. Nicotine's action and the pathobiology of schizophrenic disorders have common neurobiological substrates. Tobacco smoking alters medication blood levels and effectiveness, modifies psychiatric symptoms, and is a clue for other substance abuse. This article presents an evaluation of a smoking cessation program for 24 smokers with schizophrenia. Fifty percent completed the program, 40 percent decreased use by 50 percent, and 13 percent remained abstinent (carbon monoxide verified) for 6 months. Nicotine replacement, motivational enhancement therapy, and relapse prevention behavioral therapy were important components of treatment. Pharmacotherapy strategies of a higher-dose nicotine patch, combining nicotine gum and a patch, and augmentation medication to nicotine replacement should be evaluated in future studies in this population.